Market cap
$116 Mln
Recently Viewed
Clear AllMarket cap
$116 Mln
Revenue (TTM)
$52 Mln
P/E Ratio
--
P/B Ratio
11.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-3.3 %
ROCE
-- %
Industry P/E
22.29
EV/EBITDA
-2.4
Debt to Equity
1.5
Book Value
$--
EPS
$-0.5
Face value
--
Shares outstanding
49,428,100
CFO
$-99.75 Mln
EBITDA
$-84.01 Mln
Net Profit
$-99.96 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Augmedix Inc (AUGX)
| -59.8 | 1.3 | 152.7 | -54.4 | -26.8 | -- | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Augmedix Inc (AUGX)
| 275.0 | -50.5 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go... Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was formerly known as Malo Holdings Corporation and changed its name to Augmedix, Inc. in October 2020. The company was founded in 2013 and is headquartered in San Francisco, California. Read more
President, CEO, Secretary & Director
Mr. Emmanuel Krakaris
President, CEO, Secretary & Director
Mr. Emmanuel Krakaris
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Augmedix Inc (AUGX) is $2.35 (NASDAQ) as of 02-Oct-2024 09:30 EDT. Augmedix Inc (AUGX) has given a return of -26.83% in the last 3 years.
Since, TTM earnings of Augmedix Inc (AUGX) is negative, P/E ratio is not available.
The P/B ratio of Augmedix Inc (AUGX) is 11.09 times as on 02-Oct-2024, a 376 premium to its peers’ median range of 2.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-14.96
|
12.30
|
|
2022
|
-2.20
|
39.84
|
|
2021
|
-6.36
|
4.61
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Augmedix Inc (AUGX) are Rs -- and Rs -- as of 25-Apr-2026.
Augmedix Inc (AUGX) has a market capitalisation of $ 116 Mln as on 02-Oct-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Augmedix Inc (AUGX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.